Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

together are uniquely positioned to help medical providers and patients understand the clinical promise and economic value of denosumab."

"This pioneering treatment that Amgen has developed will be a strong addition to our biopharmaceuticals portfolio," commented Andrew Witty, CEO of GlaxoSmithKline. "The data for denosumab is very encouraging and we believe it will provide significant benefit and value to patients with postmenopausal osteoporosis and other bone disease conditions. Together with Amgen we are committed to increasing worldwide access to this medicine."

In July 2007, Amgen granted Daiichi Sankyo exclusive rights to develop and commercialize denosumab in Japan in PMO and oncology with the potential for additional indications. This arrangement remains in place.

About Denosumab

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone. With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs.

Amgen has submitted marketing applications for denosumab in the United States, European Union, Canada, Switzerland, and Australia.

About Osteoporosis

Often referred to as the "silent epidemic," osteoporosis is a global problem that is
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The National Model Aviation Museum, located ... pleased to announce that it has been granted full ... United States Air Force. , The certification is the ... this spring with an on-site inspection by Sarah Sessions, ... The National Museum of the United States Air ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 Canada ... key market data on the Canada Endoscopy Visualization ... of US dollars, volume (in units) and average ... High-End Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems ... Report at http://www.marketresearchreports.biz/analysis/213254 . , The report ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... July 25, 2014 Amgen (NASDAQ: ... declared a $0.61 per share dividend for the third ... Sept. 5, 2014, to all stockholders of record as ... About Amgen Amgen is committed to ... serious illnesses by discovering, developing, manufacturing and delivering innovative ...
Breaking Biology Technology:AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... ,, Collaboration is part of Aeterna Zentaris, strategy of personalized ... targeted conjugate with doxorubicin, being investigated in multiple cancers , ... QUÉBEC ... (TSX: AEZ; Nasdaq: AEZS ), (the "Company"), a late-stage ...
... ... in Arizona ,with State of the Art 3D Dedicated Neurology Suite, , ... (PRWEB) June 28, 2010 -- ... in the state of Arizona to adopt TrueVision® 3D Surgical Visualization, where multiple 3D ...
... ORLANDO, Fla. , June 26, 2010 ... Lilly and Company (NYSE: LLY ) today ... than 260,000 patients that showed the risk of acute ... increased compared to initiators of other antidiabetic therapies. These ...
Cached Biology Technology:Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 2Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 3Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer 4Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 3Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 4Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 5Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 6Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 7Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 8
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... A new in vitro study has revealed that nicotine ... DNA damage caused by a certain carcinogen in smoke. ... the curing of tobacco leaves and ultimately ends up ... in the lung and liver, where it is activated ... Previous research in mice has revealed that nicotine can ...
(Date:7/27/2014)... strike that wiped them out if it had taken ... , A fresh study using up-to-date fossil records and ... new narrative of the prehistoric creatures, demise, some 66 ... few million years before a 10km-wide asteroid struck what ... included extensive volcanic activity, changing sea levels and varying ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Dinosaurs fell victim to perfect storm of events, study shows 2
... into our brain, and new research by University of ... known that fear and other highly emotional experiences lead ... today (Tuesday, June 14) in advance of publication in ... Kaufer and colleagues report a new way for emotions ...
... , This release is available in Spanish ... mixes are a produce section favorite. They offer convenience, selection, ... from the chore of washing and chopping, slicing, or shredding ... time to time, been associated with bagged salad greens. The ...
... to replace lost teeth with titanium dental implants could be ... only at micro level but also at nano level, researchers ... a method that could shorten the healing time for patients. ... the conductivity of the implant allows us to affect the ...
Cached Biology News:Fear boosts activation of young, immature brain cells 2Fear boosts activation of young, immature brain cells 3Scientists pitch in to help keep salad mixes safe to eat 2Healing times for dental implants could be cut 2
... many modifications to the original formulas in efforts ... play an important role in tissue,culture. A salt ... osmotic balance in the medium and to provide ... is as valuable today as when it was ...
A substrate for all AChE-based EIA kits....
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... These are just some the things youll ... of Protein-Protein Interactions, edited by Erica Golemis, One ... skillfully edited compilation of topics in protein interaction ... text that must be a part of your ...
Biology Products: